Clinical efficacy of first and second series of peptide receptor radionuclide therapy in patients with neuroendocrine neoplasm: a cohort study

References

• Lawrence B, Gustafsson BI, Chan A, et al. The epidemiology of gastroenteropancreatic neuroendocrine tumors. Endocrinol Metab Clin North Am. 2011;40(1):1–18, vii.
   PubMed Web of Science ®Google Scholar
• Oberg K. Biotherapies for GEP-NETs. Best Pract Res Clin Gastroenterol. 2012;26(6):833–841.
   PubMed Web of Science ®Google Scholar
• Uri I, Avniel-Polak S, Gross DJ, et al. Update in the Therapy of Advanced Neuroendocrine Tumors. Curr Treat Options Oncol. 2017;18(12):72.
   PubMed Web of Science ®Google Scholar
• Reubi JC, Waser B. Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptor tumour targeting. Eur J Nucl Med Mol Imaging. 2003;30(5):781–793.
   PubMed Web of Science ®Google Scholar
• Oberg KE, Reubi JC, Kwekkeboom DJ, et al. Role of somatostatins in gastroenteropancreatic neuroendocrine tumor development and therapy. Gastroenterology. 2010;139(3):742–753. 53.e1.
   PubMed Web of Science ®Google Scholar
• Chan J, Kulke M. Targeting the mTOR signaling pathway in neuroendocrine tumors. Curr Treat Options Oncol. 2014;15(3):365–379.
   PubMed Web of Science ®Google Scholar
• Faivre S, Niccoli P, Castellano D, et al. Sunitinib in pancreatic neuroendocrine tumors: updated progression-free survival and final overall survival from a phase III randomized study. Ann Oncol. 2017;28(2):339–343.
   PubMed Web of Science ®Google Scholar
• Naidoo J, O'Toole D, Kennedy MJ, et al. A single institution experience of streptozocin/fluorouracil combination chemotherapy: a case series. Ir J Med Sci. 2012;181(2):211–214.
   PubMed Web of Science ®Google Scholar
• Ramirez RA, Beyer DT, Chauhan A, et al. The role of capecitabine/temozolomide in metastatic neuroendocrine tumors. Oncologist. 2016;21(6):671–675.
   PubMed Web of Science ®Google Scholar
• Imhof A, Brunner P, Marincek N, et al. Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers. J Clin Oncol. 2011;29(17):2416–2423.
   PubMed Web of Science ®Google Scholar
• Brabander T, van der Zwan WA, Teunissen JJM, et al. Long-term efficacy, survival, and safety of [177Lu-DOTA0,Tyr3]octreotate in patients with gastroenteropancreatic and bronchial neuroendocrine tumors. Clin Cancer Res. 2017;23(16):4617–4624.
   PubMed Web of Science ®Google Scholar
• Bodei L, Cremonesi M, Grana C, et al. Receptor radionuclide therapy with 90Y-[DOTA]0-Tyr3-octreotide (90Y-DOTATOC) in neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2004;31(7):1038–1046.
   PubMed Web of Science ®Google Scholar
• Severi S, Grassi I, Nicolini S, et al. Peptide receptor radionuclide therapy in the management of gastrointestinal neuroendocrine tumors: efficacy profile, safety, and quality of life. Onco Targets Ther. 2017;10:551–557.
   PubMed Web of Science ®Google Scholar
• Kwekkeboom DJ, de Herder WW, Kam BL, et al. Treatment with the radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol. 2008;26(13):2124–2130.
   PubMed Web of Science ®Google Scholar
• Strosberg J, El-Haddad G, Wolin E, et al. Phase 3 trial of 177Lu-dotatate for midgut neuroendocrine tumors. N Engl J Med. 2017;376(2):125–135.
   PubMed Web of Science ®Google Scholar
• Sharma N, Naraev BG, Engelman EG, et al. Peptide receptor radionuclide therapy outcomes in a North American cohort with metastatic well-differentiated neuroendocrine tumors. Pancreas. 2017;46(2):151–156.
   PubMed Web of Science ®Google Scholar
• van der Zwan WA, Brabander T, Kam BLR, et al. Salvage peptide receptor radionuclide therapy with [177Lu-DOTA,Tyr3]octreotate in patients with bronchial and gastroenteropancreatic neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2019;46(3):704–717.
   PubMed Web of Science ®Google Scholar
• Bodei L, Mueller-Brand J, Baum RP, et al. The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2013;40(5):800–816.
   PubMed Web of Science ®Google Scholar
• Pfeifer AK, Gregersen T, Grønbaek H, et al. Peptide receptor radionuclide therapy with Y-DOTATOC and 177Lu-DOTATOC in advanced neuroendocrine tumors: results from a Danish cohort treated in Switzerland. Neuroendocrinology. 2011;93(3):189–196.
   PubMed Web of Science ®Google Scholar
• Arveschoug AK, Kramer SM, Iversen P, et al. Monitoring kidney function in neuroendocrine tumor patients treated with 90Y-DOTATOC: associations with risk factors. Curr Radiopharm. 2015;8(1):49–55.
   PubMed Web of Science ®Google Scholar
• Nicolas G, Giovacchini G, Müller-Brand J, et al. Targeted radiotherapy with radiolabeled somatostatin analogs. Endocrinol Metab Clin North Am. 2011;40(1):187–204. ix-x.
   PubMed Web of Science ®Google Scholar
• Valkema R, Pauwels SA, Kvols LK, et al. Long-term follow-up of renal function after peptide receptor radiation therapy with 90Y-DOTA0,Tyr3-octreotide and 177Lu-DOTA(0), Tyr3-octreotate. J Nucl Med. 2005;46(Suppl 1):83s–91s.
   PubMed Web of Science ®Google Scholar
• Rolleman EJ, Valkema R, de Jong M, et al. Safe and effective inhibition of renal uptake of radiolabelled octreotide by a combination of lysine and arginine. Eur J Nucl Med Mol Imaging. 2003;30(1):9–15.
   PubMed Web of Science ®Google Scholar
• Bodei L, Cremonesi M, Zoboli S, et al. Receptor-mediated radionuclide therapy with 90Y-DOTATOC in association with amino acid infusion: a phase I study. Eur J Nucl Med Mol Imaging. 2003;30(2):207–216.
   PubMed Web of Science ®Google Scholar
• Harris PA, Taylor R, Thielke R, et al. Research electronic data capture (REDCap)-a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42(2):377–381.
   PubMed Web of Science ®Google Scholar
• Common Terminology Criteria for Adverse Events v3.0 (CTCAE) August 9, 2006. [cited 2021 Jan 4]. Available from: https://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf
   Google Scholar
• Ezziddin S, Khalaf F, Vanezi M, et al. Outcome of peptide receptor radionuclide therapy with 177Lu-octreotate in advanced grade 1/2 pancreatic neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2014;41(5):925–933.
   PubMed Web of Science ®Google Scholar
• Ezziddin S, Attassi M, Yong-Hing CJ, et al. Predictors of long-term outcome in patients with well-differentiated gastroenteropancreatic neuroendocrine tumors after peptide receptor radionuclide therapy with 177Lu-octreotate. J Nucl Med. 2014;55(2):183–190.
   PubMed Web of Science ®Google Scholar
• Bodei L, Schöder H, Baum RP, et al. Molecular profiling of neuroendocrine tumours to predict response and toxicity to peptide receptor radionuclide therapy. Lancet Oncol. 2020;21(9):e431–e443.
   PubMed Web of Science ®Google Scholar
• Hirmas N, Jadaan R, Al-Ibraheem A. Peptide receptor radionuclide therapy and the treatment of gastroentero-pancreatic neuroendocrine tumors: current findings and future perspectives. Nucl Med Mol Imaging. 2018;52(3):190–199.
   PubMed Web of Science ®Google Scholar
• Aalbersberg EA, Huizing DM, Walraven I, et al. Parameters to predict progression free and overall survival after peptide receptor radionuclide therapy: a multivariate analysis in 782 patients. J Nucl Med. 2019;60(9):1259–1265.
   PubMed Web of Science ®Google Scholar
• Ezziddin S, Logvinski T, Yong-Hing C, et al. Factors predicting tracer uptake in somatostatin receptor and MIBG scintigraphy of metastatic gastroenteropancreatic neuroendocrine tumors. J Nucl Med. 2006;47(2):223–233.
   PubMed Web of Science ®Google Scholar
• Kayani I, Bomanji JB, Groves A, et al. Functional imaging of neuroendocrine tumors with combined PET/CT using 68Ga-DOTATATE (DOTA-DPhe1,Tyr3-octreotate) and 18F-FDG. Cancer. 2008;112(11):2447–2455.
   PubMed Web of Science ®Google Scholar
• Carlsen EA, Fazio N, Granberg D, et al. Peptide receptor radionuclide therapy in gastroenteropancreatic NEN G3: a multicenter cohort study. Endocr Relat Cancer. 2019;26(2):227–239.
   PubMed Web of Science ®Google Scholar
• Vaughan E, Machta J, Walker M, et al. Retreatment with peptide receptor radionuclide therapy in patients with progressing neuroendocrine tumours: efficacy and prognostic factors for response. Br J Radiol. 2018;91(1091):20180041.
   PubMed Web of Science ®Google Scholar
• Severi S, Sansovini M, Ianniello A, et al. Feasibility and utility of re-treatment with (177)Lu-DOTATATE in GEP-NENs relapsed after treatment with (90)Y-DOTATOC. Eur J Nucl Med Mol Imaging. 2015;42(13):1955–1963.
   PubMed Web of Science ®Google Scholar
• Yordanova A, Mayer K, Brossart P, et al. Safety of multiple repeated cycles of (177)Lu-octreotate in patients with recurrent neuroendocrine tumour. Eur J Nucl Med Mol Imaging. 2017;44(7):1207–1214.
   PubMed Web of Science ®Google Scholar
• Sabet A, Haslerud T, Pape UF, et al. Outcome and toxicity of salvage therapy with 177Lu-octreotate in patients with metastatic gastroenteropancreatic neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2014;41(2):205–210.
   PubMed Web of Science ®Google Scholar
• Rudisile S, Gosewisch A, Wenter V, et al. Salvage PRRT with 177Lu-DOTA-octreotate in extensively pretreated patients with metastatic neuroendocrine tumor (NET): dosimetry, toxicity, efficacy, and survival. BMC Cancer. 2019;19(1):788.
   PubMed Web of Science ®Google Scholar